Decanoic acid additively suppresses IL-1β and enables pharmacologic dexamethasone dose-sparing in LPS/ATP-stimulated THP-1 macrophages
9 affiliations
- 1Trauma Research, Swedish Medical Center, Englewood, Colorado, United States of America.
- 2Trauma Research, Wesley Medical Center, Wichita, Kansas, United States of America.
- 3Trauma Research, Lutheran Medical Center, Wheat Ridge, Colorado, United States of America.
- 4Trauma Research, South Texas Health System, McAllen, Texas, United States of America.
- 5Trauma Services, Swedish Medical Center, Englewood, Colorado, United States of America.
- 6Emergency Services, Wesley Medical Center, Wichita, Kansas, United States of America.
- 7Trauma Services, Lutheran Medical Center, Wheat Ridge, Colorado, United States of America.
- 8Trauma Services, South Texas Health System, McAllen, Texas, United States of America.
- 9Department of Molecular Biology, Rocky Vista University, Parker, Colorado, United States of America.
Abstract
Systemic inflammatory response syndrome, driven by trauma or infection, involves excessive innate immune activation. Dexamethasone (DEX), a synthetic glucocorticoid, suppresses inflammation, although adverse side effects limit its clinical use. The inflammasome, a multiprotein complex that assembles in response to inflammatory stimuli like ATP after lipopolysaccharide (LPS) priming, facilitates caspase-1 cleavage and release of the proinflammatory cytokine, interleukin (IL)-1β. We investigated whether DEX and decanoic acid (DA), a saturated medium-chain fatty acid, inhibited caspase-1 activity and IL-1β release in an LPS/ATP-stimulated THP-1 macrophage model and whether co-treatment would allow for pharmacologic DEX dose-sparing in vitro. PMA-differentiated THP-1macrophages were primed with LPS overnight and stimulated with ATP for 3 h in the presence of DA, DEX, or both. Viability and cytotoxicity were assessed. Caspase-1 activity and IL-1β were quantified, and EC50 values were calculated by nonlinear regression. In control conditions, LPS/ATP stimulation induced 5.56 (q1: 3.51 – q3: 6.38) ng/mL of IL-1β release. DA and DEX inhibited IL-1β with full dose-response EC50 values of 131.7 μM and 24.29 nM, respectively. DA concentrations exceeding 800 μM decreased cell viability. An 8 x 9-point DA/DEX dose matrix (0–500 μM DA; 0 to 1e4 nM DEX) was used to interrogate drug interaction for IL-1β inhibition and caspase-1 activity. DEX EC50 values remained within a narrow 95% confidence interval of 17.5–26.6 nM, regardless of DA background concentration. DA reduced caspase-1 enzymatic activity with a calculated EC50 value of ~140 μM; whereas, DEX did not. These data show that DA and DEX act independently. Furthermore, compared to DEX alone, the presence of DA allowed for equivalent in vitro IL-1β suppression at lower DEX concentrations, supporting pharmacologic DEX dose-sparing. Determination of whether this pharmacologic effect translates to clinically meaningful corticosteroid dose reduction requires further study.
Related
- Extract-equivalent decursin and decursinol angelate reproduce major anti-inflammatory effects of Angelica gigas root ethanol extract in LPS-stimulated macrophages
- Cell-intrinsic complement C3 suppresses IFN-β production in macrophages
- Activation of KCa3.1 K⁺ Channel Suppresses COX2- and ARG1-Dependent Immunosuppressive Metabolic Programs in THP-1-Derived M₂-like Macrophages.
- p53 activation via pharmacologic MDM2 inhibition constrains exhaustion and enhances antitumor function of human CD8+ T cells
- Pharmacologic modulation of orexin signaling: Impact on glucose–insulin homeostasis and potential mechanism of antidepressant action
BibTeX
@article{hausburg2026decanoic,
title = {{Decanoic acid additively suppresses IL-1β and enables pharmacologic dexamethasone dose-sparing in LPS/ATP-stimulated THP-1 macrophages}},
author = {Melissa A Hausburg and Kaysie L Banton and Christopher D Cassidy and Robert M Madayag and Carlos H Palacio and Jason S Williams and Gregory W Thomas and Raphael Bar-Or and David Bar-Or},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0361029},
url = {https://doi.org/10.1371/journal.pone.0361029},
note = {CC BY},
}
RIS
TY - JOUR
TI - Decanoic acid additively suppresses IL-1β and enables pharmacologic dexamethasone dose-sparing in LPS/ATP-stimulated THP-1 macrophages
AU - Melissa A Hausburg
AU - Kaysie L Banton
AU - Christopher D Cassidy
AU - Robert M Madayag
AU - Carlos H Palacio
AU - Jason S Williams
AU - Gregory W Thomas
AU - Raphael Bar-Or
AU - David Bar-Or
PY - 2026
DA - 2026/10/22
JO - PLOS One
DO - 10.1371/journal.pone.0361029
UR - https://doi.org/10.1371/journal.pone.0361029
AB - Systemic inflammatory response syndrome, driven by trauma or infection, involves excessive innate immune activation. Dexamethasone (DEX), a synthetic glucocorticoid, suppresses inflammation, although adverse side effects limit its clinical use. The inflammasome, a multiprotein complex that assembles in response to inflammatory stimuli like ATP after lipopolysaccharide (LPS) priming, facilitates caspase-1 cleavage and release of the proinflammatory cytokine, interleukin (IL)-1β. We investigated whether DEX and decanoic acid (DA), a saturated medium-chain fatty acid, inhibited caspase-1 activity and IL-1β release in an LPS/ATP-stimulated THP-1 macrophage model and whether co-treatment would allow for pharmacologic DEX dose-sparing in vitro. PMA-differentiated THP-1macrophages were primed with LPS overnight and stimulated with ATP for 3 h in the presence of DA, DEX, or both. Viability and cytotoxicity were assessed. Caspase-1 activity and IL-1β were quantified, and EC50 values were calculated by nonlinear regression. In control conditions, LPS/ATP stimulation induced 5.56 (q1: 3.51 – q3: 6.38) ng/mL of IL-1β release. DA and DEX inhibited IL-1β with full dose-response EC50 values of 131.7 μM and 24.29 nM, respectively. DA concentrations exceeding 800 μM decreased cell viability. An 8 x 9-point DA/DEX dose matrix (0–500 μM DA; 0 to 1e4 nM DEX) was used to interrogate drug interaction for IL-1β inhibition and caspase-1 activity. DEX EC50 values remained within a narrow 95% confidence interval of 17.5–26.6 nM, regardless of DA background concentration. DA reduced caspase-1 enzymatic activity with a calculated EC50 value of ~140 μM; whereas, DEX did not. These data show that DA and DEX act independently. Furthermore, compared to DEX alone, the presence of DA allowed for equivalent in vitro IL-1β suppression at lower DEX concentrations, supporting pharmacologic DEX dose-sparing. Determination of whether this pharmacologic effect translates to clinically meaningful corticosteroid dose reduction requires further study.
SN - 1932-6203
ER -